產品系列 / 解決方案: Point-of-Care Testing Solutions

FEATURE

SPECIFICATION

PERFORMANCE

The clinical performance of the GB COVID-19 Ag POCT was established with individual symptomatic patients who were suspected of COVID-19. The results are as follows：

Positive percent agreement (PPA): 96.72% (95% CI: 88.65% – 99.60%)Negative percent agreement (NPA): 97.33% (95% CI: 90.70% – 99.68%)Accuracy: 97.06% (95% CI: 92.64% – 99.19%)

ORDERING INFORMATION

PRODUCT DESCRIPTION

The GB COVID-19 Ag POCT is a qualitative membrane-based lateral flow immunoassay technology based on the double antibody-sandwich method. Using this test allows for the rapid detection of nucleocapsid protein from the SARS-CoV-2 swab from patients who are suspected of COVID-19.

FEATURE

SPECIFICATION

PERFORMANCE

The clinical performance of the GB COVID-19 Ag POCT was established with individual symptomatic patients who were suspected of COVID-19. The results are as follows：

Positive percent agreement (PPA): 94.05% (95% CI: 86.65% – 98.04%)Negative percent agreement (NPA): 98.14% (95% CI: 96.00% – 99.32%)Accuracy: 97.30% (95% CI: 95.22% – 98.64%)

ORDERING INFORMATION